BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Pfizer

The companies are the first COVID vaccine makers in the nation to apply for full approval, which would allow Pfizer to market the vaccine directly to consumers.

Pfizer-BioNTech seeks full FDA approval for COVID-19 vaccine

The Pfizer shot was the first Covid-19 vaccine to be approved under an emergency use authorization in December.

Pfizer Submits Application For Full FDA Approval Of Covid-19 Vaccine

Pfizer and BioNTech have started the regulatory process of seeking full approval for their Covid-19 vaccine for use in people 16 and older in the U.S.

Pfizer and BioNtech begin the process of seeking full FDA approval for their Covid vaccine

Pfizer Inc. and German partner BioNTech SE said Friday they have initiated rolling submission of a Biologics License Application (BLA) with the U.S. Food and Drug Administration for full approval of their COVID-19 vaccine in individuals 16 years of age and older. The vaccine was already granted emergency use authorization last December, a measure used by the FDA in emergency situations.

Pfizer and BioNTech start process of seeking full FDA approval of their COVID-19 vaccine

NEW YORK and MAINZ, GERMANY, May 7, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older. Data to support the BLA will be submitted by the Companies to the FDA on a rolling basis over the coming weeks, with a request for Priority Review. The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA will be set once the BLA is complete and formally accepted for review by the agency.

Pfizer and BioNTech Initiate Rolling Submission of Biologics License Application for U.S. FDA Approval of their COVID-19 Vaccine

Johnson & Johnson

Moderna

Novavax

AstraZeneca

Pfizer fell Thursday by as much as 5% from Wednesday's close while Moderna dipped by almost 12% before both stocks recovered most of those losses.

Covid vaccine makers' shares seesaw after Biden administration says it will back patent waivers

Vaccine stocks — including BioNTech and Moderna stocks — pared deep losses Thursday after German Chancellor Angela Merkel said that she opposed waiving Covid vaccine patent rights. The post Vaccine Stocks Pare Deep Losses As Angela Merkel Opposes Waiving Patents appeared first on Investor's Business Daily.

Vaccine Stocks Pare Deep Losses As Angela Merkel Opposes Waiving Patents

Coty

Duke Energy

Workhorse Group

As usual, even in a week when 1,500 U.S.-listed companies are reporting quarterly results, Friday afternoon hits the pause button.

Earnings Previews: BioNTech, Coty, Duke Energy, Workhorse

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) are donating doses of their COVID-19 vaccine to athletes participating in this summer's Olympic and Paralympic Games in Tokyo. What Happened: The pharmaceutical companies have signed a Memorandum of Understanding with the International Olympic Committee (IOC) to facilitate the vaccinations in conjunction with the National Olympic Committees that are sending athletes to the quadrennial events.

Pfizer And BioNTech Donate COVID-19 Vaccine To Tokyo Olympians

Moderna Inc (NASDAQ:MRNA) and Pfizer Inc. (NYSE:PFE) had a double dose of good news regarding their COVID-19 vaccines. Moderna said that its tweaked jab was successful in neutralising the South African and Brazilian variants of the virus in laboratory trials.

Coronavirus: Moderna says tweaked vaccine works against variants, two BioNTech/Pfizer doses give 95% protection

Pfizer Inc. and German partner BioNTech SE said Thursday they have signed a memorandum of understanding with the International Olympic Committee to donate their COVID-19 vaccine to help vaccinate athletes participating in this year's Olympic and Paralympic Games Tokyo 2020, which are scheduled to begin on July 23, 2021. Under the terms of the MOU, the companies will coordinate with the IOC to understand the need for vaccine doses for national delegations.

Pfizer and BioNTech to supply IOC with COVID-19 vaccines for Olympic and Paralympic Games athletes

If enacted, such a move would hit the smaller vaccine makers particularly hard.

Biden Administration Supports Patent Waivers for Coronavirus Vaccine

Health Canada authorized the company's COVID-19 vaccine for kids ages 12 to 15.

Why BioNTech Stock Is Jumping Again Today

The country's health agency credited the change to Pfizer's March trial data in adolescents.

Canada Approves Use Of Pfizer Covid Vaccine In 12- To 15-Year-Olds

Shares of Pfizer Inc. gained 2.5% in trading on Wednesday after Canadian regulators said they authorized using the company's COVID-19 vaccine for children between the ages of 12 and 15 years old. Pfizer developed the vaccine in partnership with BioNTech SE.

Canada authorizes Pfizer's COVID-19 vaccine for kids between the ages of 12 and 15 years old

Shares of BioNTech SE (NASDAQ: BNTX), which partnered with Pfizer Inc. (NYSE: PFE) in successfully developing a vaccine against the coronavirus, have been gaining ground. BioNTech's Price Action: BioNTech and its partner Pfizer received in mid-December authorization for emergency use of the BNT162b2 mRNA vaccine against the novel coronavirus that causes COVID-19.

This COVID-19 Vaccine Stock Quietly Soared 75% In April: Is There More Upside Ahead?

Probably not, but the study could benefit another vaccine maker.

Should Pfizer and Moderna Be Worried About This New COVID Vaccine Study?

Pfizer Inc.'s ( PFE , Financial) Covid-19 vaccine is poised to knock AbbVie Inc.'s ( ABBV , Financial) Humira off the top perch and become the best-selling medication in pharmaceutical industry history.

Pfizer Covid Vaccine Set to Become Highest-Selling Medication Ever

Pfizer Inc.'s COVID-19 vaccine is on track to generate a whopping $26 billion in sales this year, making it the drug maker's top-selling drug and forging a new path into infectious diseases for the legacy drug maker.

Pfizer's next play: A vaccine maker and pandemic ‘partner' to governments

BioNTech SE Sponsored ADR (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

BioNTech SE Sponsored ADR (BNTX) Stock Jumps 11%: Will It Continue to Soar?

Full FDA approval would allow the vaccine to be administered after the Covid-19 pandemic ends.

Pfizer Will File For Full FDA Approval For Covid-19 Vaccine By End Of May

Pfizer Inc. significantly increased revenue projections from its Covid-19 vaccine for the year, as sales from the shot over the first three months of 2021 lifted the company to a stronger quarterly profit.

Pfizer's COVID-19 vaccine lifts quarterly results

Mainz, Germany, Ma y 4 , 2021 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2021 on Monday, May 10th, 2021. BioNTech invites investors and the general public to join a conference call and webcast with investment analysts on the same day at 8.00 a.m. EDT (2.00 p.m. CEST) to report its financial results and provide a corporate update for the first quarter 2021.

BioNTech to Report First Quarter 2021 Financial Results and Operational Update on May 10, 2021

The Food and Drug Administration has plans to authorize the emergency use of Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) jointly-developed COVID-19 vaccine in adolescents aged between 12 to 15 years, the New York Times reported Monday. What Happened: The move means that the campaign to vaccinate against COVID-19 will potentially expand to millions more, as per the Times.

Pfizer COVID-19 Vaccine Expected To Get FDA Emergency Approval For Age Group 12-15 Next Week

Pfizer Inc. PFE is expected to get Food and Drug Administration approval for use of its COVID-19 vaccine in children aged 12 to 15, according to a report late Monday. Unnamed federal officials told The New York Times that the approval could come as early as late this week.

News for BioNTech SE Stock (BNTX)